Clinical trials: Human Papillomavirus Infections
HIV Infections, Human Papillomavirus Infection
Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV
This is a cross-sectional, observational study of high-risk HPV status, cervical cytology and HPV vaccine uptake and response in young women with perinatally acquired HIV.
- Conditions
- HIV Infections, Human Papillomavirus Infection, Cervical Cancer
- Trial name
- SHiP (NCT04587050)
- Testing
- Human papillomavirus testing, Cervical cytology, HPV serology
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Imperial College London
Infections, Papillomavirus
Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study
This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in…
- Trial name
- NCT01190189
- Testing
- GSK580299 (Cervarix)
- Where
- 28 sites in United States, Canada
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neoplasms, Squamous Cell, Papillomavirus Infections
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
The purpose of this study is to determine whether a model can be created to predict the progression of early anal cancer precursor lesions in HIV using potential predictors such as: HIV treatment history, smoking history, sexual…
- Trial name
- NCT01709448
- Where
- 2 sites in United States
- Volunteers
- 165 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Common Warts (Verruca Vulgaris), Common Warts
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4.
- Conditions
- Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-4 (NCT07457918)
- Testing
- Cantharidin
- Where
- 12 sites in United States, Japan
- Volunteers
- 250 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Cervical Cancer, Cervical Dysplasia
Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study
In Singapore, the current cervical cancer screening uptake among women in Singapore has remained at low 50% since its introduction in 2004.
- Conditions
- Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection
- Trial name
- NCT03813576
- Testing
- Self-collected HPV vaginal swab
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Papillomavirus Infections
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
- Trial name
- NCT00157950
- Testing
- Gardasil™
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV Infection
Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial
A 3-dose HPV vaccination scheme has shown to be safe and immunogenic in people living with HIV (PLWH), although evidence on 1-dose, which is important to improve coverage, is scarce.
- Trial name
- H2VICTORY (NCT05173324)
- Testing
- HPV vaccine, HPV testing, HAV vaccine
- Volunteers
- 8,000 people
- Sponsor
- International Agency for Research on Cancer
Human Papillomavirus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
The purpose of this study is to provide data on the performance of the APTIMA HPV Assay using the TIGRIS System in detecting HPV types that may cause cervical cancer.
- Trial name
- NCT00973362
- Testing
- APTIMA HPV Assay, FDA-Approved HPV DNA Test
- Where
- 17 sites in United States
- Volunteers
- 12,896 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Human Papillomavirus (HPV) Infection
HPV Detection Using Self-Collected Menstrual Blood
This study is evaluating whether human papillomavirus (HPV) can be accurately detected from self-collected menstrual blood samples.
- Trial name
- NCT07733557
- Testing
- Endometrics Menstrual Blood Collection Kit
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Samantha Batman
Infections, Papillomavirus
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00169494
- Testing
- HPV-16/18 L1/AS04
- Where
- 17 sites in Denmark, Estonia and 4 more
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)
The study evaluates if there is relationship between the kinds of bacteria living in the anus (also known as the anal microbiome) and the risk of human papillomavirus (HPV) infection or HPV-related pre-cancer (high-grade squamous…
- Conditions
- Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, High-Grade Squamous Intraepithelial Lesions
- Trial name
- ULACNet-104 (NCT06651957)
- Testing
- Biospecimen Collection, Questionnaires
- Where
- 3 sites in United States, Mexico and 1 more
- Volunteers
- 217 people
- Sponsor
- University of California, San Francisco
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Warts
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks.
- Trial name
- NCT00116662
- Testing
- Resiquimod
- Where
- 10 sites in United States
- Volunteers
- 84 people
- Sponsor
- Graceway Pharmaceuticals, LLC
HPV Infection, Vaccine Preventable Disease
Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania
Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged ~14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to…
- Trial name
- Add-Vacc (NCT04953130)
- Testing
- Gardasil® HPV vaccine
- Where
- Tanzania
- Volunteers
- 10,400 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
High Risk Human Papillomavirus Infection, Low Grade Squamous Intraepithelial Lesion
Evaluation of AHCC® for the Clearance of High Risk-HPV Infections in Chinese Female
This is a multi-centre, randomised, double blind, placebo-controlled study on female participants with diagnosis of high-risk human papillomavirus (HR-HPV) infection to evaluate the clearance capacity of AHCC®.
- Trial name
- NCT04633330
- Testing
- AHCC®capsules, Simulation of AHCC®capsules
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong University
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer
SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells
This randomized phase II trial is studying how well SGN-00101 vaccine works compared to a placebo in treating human papillomavirus and preventing cervical cancer in patients with abnormal cervical cells.
- Conditions
- Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
- Trial name
- NCT00091130
- Testing
- HspE7, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Transplantation, Systemic Lupus Erythematosus
Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.
PRIMAVERA is a Phase IIa clinical trial, with the objective to assess the immunologic response to HPV vaccine in a population of immunocompromised girls.
- Conditions
- Transplantation, Systemic Lupus Erythematosus, Systemic Immune Disease
- Trial name
- PRIMAVERA (NCT01687192)
- Testing
- HPV prophylactic vaccine Gardasil
- Where
- 9 sites in France
- Volunteers
- 37 people
- Sponsor
- University Hospital, Bordeaux
Human Papillomavirus Infection
Throat and Other HPV-Related Cancers in Men: Identifying Them Early
This trial studies the screening of human papillomavirus (HPV)-related oropharyngeal and anogenital cancers. Learning the relationship between HPV and cancer risk in men who test positive for HPV antibodies or circulating HPV DNA…
- Trial name
- TRINITY (NCT02897427)
- Testing
- Biomarker Analysis, Biospecimen Collection, Ultrasonography
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women.
- Conditions
- High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion, ASC-US, HPV Infection
- Trial name
- NCT07572396
- Testing
- EGCG and Quinine Sulfate Vaginal Suppository
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- Amplexd Therapeutics, Inc.